---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-23-016146"
form_type: "8-K"
ticker: "PGEN"
cik: "0001356090"
company_name: "PRECIGEN, INC."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:17:36.360910+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Precigen Q3 2023 loss per share $0.08; FDA agrees PRGN-2012 study pivotal for BLA

## Summary
- Cash and investments $79.0M as of Sep 30, 2023; cash runway projected into 2025.
- Total revenues decreased 92% to $1.3M in Q3 2023 from $16.6M in Q3 2022, largely from prior-year non-cash collaboration revenue.
- Loss from continuing operations $19.8M ($0.08 per share) vs. $7.6M ($0.04) in Q3 2022.
- FDA agreed ongoing Phase 1/2 single-arm study of PRGN-2012 in RRP will serve as pivotal for accelerated BLA; Phase 2 enrollment complete, expected completion Q2 2024.
- SG&A costs down 9% in Q3 and 17% for first nine months 2023 vs. prior year, driven by reduced professional fees.

## SEC filing metadata
- accession: 0000950103-23-016146
- form_type: 8-K
- ticker: PGEN
- cik: 0001356090
- company_name: PRECIGEN, INC.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356090/000095010323016146/0000950103-23-016146-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356090/000095010323016146/dp202678_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-23-016146
- JSON: https://secwatch.observer/filing/0000950103-23-016146.json
- Plain text: https://secwatch.observer/filing/0000950103-23-016146.txt

## Key facts
- Earnings Releases
  PRECIGEN, INC. reported financial results for third quarter 2023.
  - Period: third quarter 2023
  - Result: reported results
  source text: Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced third quarter 2023 financial results and progress of clinical programs.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1356090/000095010323016146/0000950103-23-016146-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.